Cargando…
Molecular targeted therapies for microscopic polyangiitis and granulomatosis with polyangiitis
Clinical trials and observational studies have established cyclophosphamide (CY) or rituximab plus glucocorticoid (GC) as standard remission induction therapies in patients with microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA). However, because these regimens are associated...
Autores principales: | Harigai, Masayoshi, Tsutsumino, Michi, Takada, Hideto, Nagasaka, Kenji |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Association of Internal Medicine
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506735/ https://www.ncbi.nlm.nih.gov/pubmed/30613065 http://dx.doi.org/10.3904/kjim.2018.366 |
Ejemplares similares
-
Current therapy of granulomatosis with polyangiitis and microscopic polyangiitis: the role of rituximab
por: Geetha, Duvuru, et al.
Publicado: (2014) -
Place in therapy of rituximab in the treatment of granulomatosis with polyangiitis and microscopic polyangiitis
por: Shah, Shivani, et al.
Publicado: (2015) -
Current status of the treatment of microscopic polyangiitis and granulomatosis with polyangiitis in Japan
por: Sugiyama, Koichi, et al.
Publicado: (2012) -
Long‐Term Safety of Rituximab in Granulomatosis With Polyangiitis and in Microscopic Polyangiitis
por: Merkel, Peter A., et al.
Publicado: (2021) -
Score to assess the probability of relapse in granulomatosis with polyangiitis and microscopic polyangiitis
por: Samson, Maxime, et al.
Publicado: (2023)